Lower cost Asian JE vaccine in prospect as Inviragen licenses cell tech to Vietnam producer

The US vaccines firm Inviragen has started off the new year on the right foot by meeting one of the main goals for its cell cultured Japanese encephalitis (JE) vaccine: to partner the program with a local manufacturer in an endemic region.

More from Anti-infective

More from Therapeutic Category